Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Blood ; 144(10): 1083-1092, 2024 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-38820500

RESUMO

ABSTRACT: Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? From 2012 to 2016, 373 previously untreated patients, 87% aged ≥60 years, were enrolled in this trial. At a median follow-up of 7.5 years, there is no difference in the median PFS of BR compared with BVR (5.5 vs 6.4 years; hazard ratio [HR], 0.90; 90% confidence interval [CI], 0.70-1.16). There were no unexpected additional toxicities with BVR treatment compared with BR, with no impact on total dose/duration of treatment received. Independent of the induction treatment, addition of lenalidomide did not significantly improve PFS, with median PFS in R vs LR (5.9 vs 7.2 years; HR, 0.84; 90% CI, 0.62-1.15). Most patients completed the planned 24 cycles of LR at the scheduled dose. In summary, adding bortezomib to BR induction does not prolong PFS in treatment-naïve MCL, and LR maintenance was not associated with longer PFS compared with R alone after BR. Nonetheless, the >5-year median PFS outcomes in this prospective cooperative group trial indicate the efficacy of BR followed by R maintenance as highly effective initial therapy for older patients with MCL. This trial was registered at www.clinicaltrials.gov as #NCT01415752.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Cloridrato de Bendamustina , Bortezomib , Lenalidomida , Linfoma de Célula do Manto , Quimioterapia de Manutenção , Rituximab , Humanos , Rituximab/administração & dosagem , Rituximab/uso terapêutico , Cloridrato de Bendamustina/administração & dosagem , Cloridrato de Bendamustina/uso terapêutico , Bortezomib/administração & dosagem , Bortezomib/uso terapêutico , Lenalidomida/administração & dosagem , Lenalidomida/uso terapêutico , Feminino , Masculino , Pessoa de Meia-Idade , Idoso , Linfoma de Célula do Manto/tratamento farmacológico , Linfoma de Célula do Manto/mortalidade , Linfoma de Célula do Manto/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Idoso de 80 Anos ou mais , Adulto , Quimioterapia de Indução , Intervalo Livre de Progressão
2.
Gen Dent ; 57(6): 637-43, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19906616

RESUMO

A resin acrylic and plaster solder index technique is a simple, accurate, secure, and cost-effective way to intraorally realign an ill-fitting fixed partial denture framework. Once the fixed partial denture framework is sectioned and segments are found to fit, an intraoral index preserves the correct relationship among segments and holds castings together securely enough to avoid separating until they can be embedded in solder investment and soldered in the dental laboratory. This technique is described here, together with a literature review and a discussion of the technique's advantages relative to other indexing techniques and materials.


Assuntos
Reparação em Dentadura/métodos , Prótese Parcial Fixa , Resinas Acrílicas , Sulfato de Cálcio , Soldagem em Odontologia , Humanos , Ajuste de Prótese , Ceras
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA